467 related articles for article (PubMed ID: 37913909)
1. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
2. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
[TBL] [Abstract][Full Text] [Related]
5. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
6. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
7. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
8. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
9. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Martin TG; Madduri D; Pacaud L; Usmani SZ
Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629
[TBL] [Abstract][Full Text] [Related]
10. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
Expert Opin Biol Ther; 2024 May; ():1-12. PubMed ID: 38738379
[TBL] [Abstract][Full Text] [Related]
11. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
12. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
13. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM.
Jurgens E; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):277-284. PubMed ID: 38331676
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
17. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
18. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
20. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
